Novo Nordisk A/S (NONOF)
| Previous Close | 125.50 |
| Open | 129.82 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 125.00 - 130.00 |
| 52 Week Range | 74.70 - 140.32 |
| Volume | |
| Avg. Volume | 43,357 |
| Market Cap | 578.541B |
| Beta (5Y Monthly) | 0.19 |
| PE Ratio (TTM) | 48.60 |
| EPS (TTM) | 2.67 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.86 (1.43%) |
| Ex-Dividend Date | Mar 22, 2024 |
| 1y Target Est | N/A |
Yahoo FinanceEli Lilly reports $2 billion from Mounjaro, Zepbound in Q1 2024
Eli Lilly missed on total sales in the first quarter, but its GLP-1 drugs helped boost sales by 26% over those in Q1 2023.
- Reuters
Novo Nordisk owner to invest $200 million in quantum computing startups
Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk, said on Wednesday it plans to invest around $200 million in quantum computing startups. The company, the investment arm of the Novo Nordisk Foundation, has 77% of voting shares in Novo Nordisk, which is known for producing blockbuster obesity drug Wegovy and diabetes treatment Ozempic. Experts believe quantum computing may prove to be among the most transformational technological developments of the 21st century.
Investor's Business DailyIBD Stock Of The Day Eli Lilly Surges After Weight-Loss Drug Obliterates Sales Views
Eli Lilly stock jumped Tuesday despite a mixed first-quarter report, after sales of weight-loss drug Zepbound obliterated expectations.
